Search 

China国家发改委旗下，专业社团投融资机构。

a large hospital

CICCB is an investment company, cofounded by China International Capital Corporation Limited (‘CICC’) and CCB Trust Co., Ltd. CICC is the No.1 investment bank in China which was founded in 1995 as a joint venture of China Construction Bank and Morgan Stanley. And CCB trust is the No.1 trust in China, with AUM more than 250 bn USD. In addition, CCB trust is the wholly owned subsidiary of China Construction Bank, one of Top 4 state owned banks in China. Our main business covers asset management, IPO, M&A and strategic investment for industry. Leveraged by shareholders' strong resource, CICCB's investment areas cover full value chain, including VC, PE, pre-IPO and other stages. Target industries include healthcare, TMT, consumer-related and other emerging strategic industries. As a strategic integration platform for CICC and CCB, CICCB is committed to becoming an all-round asset management institution with global influence in key areas.

中信资本

Advanced investment bank of China

Convalife is an innovative, research-based, clinical stage biopharmaceutical company focused on bringing innovative therapies to patients with cancer, autoimmune and infectious diseases in China and around the world.

Big pharm in China

CPE is a leading alternative asset manager, with asset classes spanning private equity, mezzanine and the public market. Founded in 2008 by a world class team of investment professionals and supported by over 200 domestic and international investors, CPE knows China like no one else and is a globally minded long-term value investor. The firm uses its sector expertise to generate deal flow and drive the value creation work during the post-investment stage. CPE follows a disciplined investment approach to preserve and grow its investors’ capital. The firm’s private equity portfolio of more than 100 companies is highly diversified by sector and stage of investment. CPE takes pride in its forward-looking investment philosophy and works hard to create value over the long-term for its investors and a better world.

CP pharmaceutical group is a leading healthcare player in China. Stock listed in H. K. since 2000.

A leading Chinese listed company looking for cooperation opportunities in TAs such as oncology, orthopedics, CVS, respiratory, anti infection, orphan drugs, digestive and pediatric.